Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy

Fig. 1

Combination of XRT, MerTK ASO, and αPD1 delays the growth of both the primary and the secondary tumors. A Treatment scheme for mice with 344SQR two tumor models. B Average tumor volumes and survival curves. C Individual tumor growth curves. The mice were inoculated with primary tumors and secondary tumors on the right and left legs on days 0 and 4, respectively. The primary tumors were irradiated with 3x12 Gy radiation on days 8, 9, and 10. The mice were intraperitoneally administered with 10 mg/kg αPD1 and 50 mg/kg MerTK ASO on the indicated time points in Fig. 1A. The tumor volumes were monitored from day 7 and the mice were sacrificed when any dimension of the tumors reached 14 mm. The tumors volumes were compared with two-way ANOVA and expressed as Mean±SEM. The survival curves were compared with log-rank tests. P values of <0.05 indicates statistical significance. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, NS denotes not significant

Back to article page